FY2025 Earnings Estimate for Adagene Issued By HC Wainwright

Adagene Inc. (NASDAQ:ADAG) – Research analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Adagene in a research note issued on Thursday, April 3rd. HC Wainwright analyst A. He now anticipates that the company will post earnings per share of ($0.67) for the year, up from their prior estimate of ($0.74). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Adagene’s FY2026 earnings at ($0.70) EPS, FY2027 earnings at ($1.22) EPS, FY2028 earnings at ($1.16) EPS and FY2029 earnings at ($0.50) EPS.

Separately, Morgan Stanley lowered Adagene from an “overweight” rating to an “equal weight” rating in a report on Friday, January 31st.

Adagene Stock Down 3.6 %

Shares of NASDAQ:ADAG opened at $1.58 on Monday. The firm has a 50-day simple moving average of $1.84 and a 200 day simple moving average of $2.12. Adagene has a fifty-two week low of $1.33 and a fifty-two week high of $3.58.

Hedge Funds Weigh In On Adagene

Several hedge funds and other institutional investors have recently modified their holdings of ADAG. General Atlantic L.P. lifted its position in Adagene by 1,349.2% in the 4th quarter. General Atlantic L.P. now owns 3,825,952 shares of the company’s stock valued at $7,614,000 after purchasing an additional 3,561,952 shares during the last quarter. Catalina Capital Group LLC boosted its position in shares of Adagene by 129.2% during the fourth quarter. Catalina Capital Group LLC now owns 29,198 shares of the company’s stock worth $58,000 after buying an additional 16,461 shares during the period. Mill Creek Capital Advisors LLC grew its holdings in Adagene by 119.6% in the 4th quarter. Mill Creek Capital Advisors LLC now owns 199,610 shares of the company’s stock worth $397,000 after buying an additional 108,702 shares in the last quarter. Exome Asset Management LLC increased its position in Adagene by 74.1% in the 3rd quarter. Exome Asset Management LLC now owns 262,625 shares of the company’s stock valued at $583,000 after acquiring an additional 111,749 shares during the period. Finally, Fifth Lane Capital LP bought a new stake in Adagene during the 4th quarter valued at $54,000. Institutional investors and hedge funds own 9.51% of the company’s stock.

Adagene Company Profile

Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.